Quantitative Investment Management LLC Invests $2.62 Million in Waters Corporation $WAT

Quantitative Investment Management LLC purchased a new stake in shares of Waters Corporation (NYSE:WAT) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 8,723 shares of the medical instruments supplier’s stock, valued at approximately $2,615,000.

A number of other large investors have also recently modified their holdings of WAT. Root Financial Partners LLC bought a new position in Waters in the third quarter worth approximately $26,000. ANTIPODES PARTNERS Ltd bought a new stake in Waters during the 3rd quarter valued at $26,000. Hantz Financial Services Inc. lifted its holdings in shares of Waters by 115.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 112 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 60 shares during the period. CYBER HORNET ETFs LLC purchased a new stake in shares of Waters in the 2nd quarter worth $53,000. Finally, MUFG Securities EMEA plc bought a new position in shares of Waters during the 2nd quarter worth $61,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Waters Trading Down 4.7%

Shares of NYSE WAT opened at $283.58 on Friday. Waters Corporation has a 1-year low of $275.05 and a 1-year high of $414.15. The business has a fifty day moving average price of $354.58 and a 200 day moving average price of $350.90. The stock has a market capitalization of $27.82 billion, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 2.05 and a beta of 1.20. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.73 and a quick ratio of 1.27.

Waters (NYSE:WAT) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.50 by $0.03. The company had revenue of $932.36 million for the quarter, compared to analyst estimates of $928.17 million. Waters had a return on equity of 34.79% and a net margin of 20.30%.The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.10 earnings per share. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Equities research analysts expect that Waters Corporation will post 12.86 EPS for the current fiscal year.

Analysts Set New Price Targets

WAT has been the topic of several research reports. Evercore began coverage on Waters in a research note on Tuesday, February 10th. They set a “hold” rating and a $360.00 price target on the stock. Guggenheim reiterated a “buy” rating and set a $440.00 target price on shares of Waters in a report on Tuesday, February 10th. Wall Street Zen downgraded shares of Waters from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. William Blair began coverage on shares of Waters in a report on Monday, January 5th. They issued an “outperform” rating for the company. Finally, HSBC began coverage on shares of Waters in a research report on Tuesday, January 27th. They issued a “buy” rating and a $460.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $393.84.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.